Brief: Palatin Completes Enrollment In Phase 3 Melody-1 Study Of Pl9643 For The Treatment Of Patients With Dry Eye Disease
07/09/2023 13:39
Sept 7 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN COMPLETES ENROLLMENT IN PHASE 3 MELODY-1 STUDY OF
PL9643
FOR THE TREATMENT OF PATIENTS WITH DRY EYE DISEASE
* PALATIN TECHNOLOGIES INC - TOPLINE DATA CURRENTLY EXPECTED
LATE
4Q CALENDAR 2023
Source text for Eikon: ID:nPn3nRMtza
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity